Director at Artelo Biosciences (ARTL) awarded 292 stock options at $1.71

Rhea-AI Filing Summary

Artelo Biosciences director Connie Matsui reported receiving a grant of stock options on January 30, 2026. The award covers 292 stock options, each with a $1.71 exercise price, giving the right to buy 292 shares of common stock. The options were granted at no cost and are held directly, with 292 derivative securities beneficially owned after the transaction. Vesting is contingent on Matsui continuing as a Service Provider, with all shares vesting on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MATSUI CONNIE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	292	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 292 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATSUI CONNIE

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.71	01/30/2026		A		292		(1)	01/30/2036	Common Stock	292	$0.00	292	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Connie Matsui report at Artelo Biosciences (ARTL)?

Connie Matsui reported a grant of stock options at Artelo Biosciences. On January 30, 2026, she received 292 stock options, each convertible into one share of common stock, as disclosed on a Form 4 insider transaction filing.

How many stock options were granted to Connie Matsui and at what exercise price?

Connie Matsui was granted 292 stock options with a $1.71 exercise price. These options give her the right to buy 292 shares of Artelo Biosciences common stock at $1.71 per share if and when the options vest and are exercised.

When do Connie Matsui’s Artelo Biosciences stock options vest?

The options vest 100% based on service and timing conditions. All 292 options vest on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date, assuming continued service.

What conditions must be met for Connie Matsui’s options to vest at Artelo Biosciences?

Vesting requires continued status as a Service Provider. Matsui must remain a Service Provider under the company’s plan through the applicable vesting date for all 292 options to vest under the timing framework described in the Form 4 footnote.

How many derivative securities does Connie Matsui own after this Form 4 transaction?

After the reported transaction, Connie Matsui beneficially owns 292 derivative securities. These represent the stock options granted on January 30, 2026, held in direct ownership as reported in the Form 4 filing.

What role does Connie Matsui hold at Artelo Biosciences (ARTL) in this filing?

Connie Matsui is identified as a director of Artelo Biosciences. The Form 4 indicates her relationship to the issuer is as a director, with no officer or 10% owner status checked in the reporting person’s relationship section.